Moderna, a US vaccine manufacturer, announced on Friday that it had enrolled 40% of volunteers in a large-scale phase III clinical trial of the new crown vaccine, which will be conducted in the United States. However, after the announcement, shares of Moderna closed down more than 2% on the same day. At present, Moderna is facing fierce competition from other US vaccine manufacturers, including Pfizer. < / P > < p > according to the plan, a total of 30000 volunteers will be vaccinated by Moderna, which has reached 13194. The company said 18 percent of the participants were black, Latino, American Indian and Alaskan Natives, who were hardest hit by the new coronation pandemic. < / P > < p > the recruitment of volunteers for Moderna nucleic acid vaccine mrna-1273 started in July and is expected to be completed in September. At present, Moderna and Pfizer are the two teams with the fastest progress in vaccine clinical trials in the United States. It is expected that the first new crown vaccine in the United States will be launched by the end of this year or early next year. < / P > < p > last week, Moderna signed a vaccine supply agreement with the U.S. government, which will purchase the company’s potential 100 million doses of new crown vaccine for $1.5 billion. So far, Moderna has received nearly $1 billion in funding from the U.S. government. However, Moderna is a company that has never had a vaccine commercialization case, which brings uncertainty to the prospect of large-scale production of the new crown vaccine. “It will be a real test.” “If successful, this will be the first product of Moderna,” Brad Loncar, founder of Loncar investments, a biomedical investment firm, told first financial reporters In terms of stock price, Moderna has increased by nearly 240% this year, but its share price has fallen by 20% in the past month. Mr Lonka said Moderna was in fierce competition with Pfizer and both wanted to be the first company to finish. “Both companies have released positive data on vaccines, and from the market reaction, investors seem to be more inclined to believe Pfizer’s vaccine.” Longka told the first financial reporter. Pfizer has also revealed that it has recruited 11000 volunteers for vaccination, 19% of whom are black or Latino. Pfizer and German biotechnology company biontech jointly developed the new crown vaccine is expected to submit complete emergency authorization application data to relevant departments in October this year. < / P > < p > Pfizer and biontech released data from an early clinical trial of the vaccine on Thursday, which showed that the new crown vaccine can induce an immune response comparable to that of rehabilitated patients with less side effects. On Friday, biontech’s shares surged more than 10%. The company’s share price has risen more than 43% this year. In addition to Moderna and Pfizer, Johnson & Johnson also said on Thursday that it would launch a large-scale phase III vaccine clinical trial in September and plan to recruit 60000 volunteers to verify the safety and effectiveness of the vaccine. Up to now, the U.S. government has invested more than 10 billion US dollars in the research and development of new coronal vaccines. Still, scientists still have a lot to do before the world’s most vulnerable groups are vaccinated. FDA has warned that adverse events may occur in large-scale clinical trials, so it is very important to do a good job in post marketing supervision. According to the guidance document for the development and authorization of new coronal vaccine issued by FDA, the premise of vaccine approval is that “the main effective endpoint of placebo-controlled efficacy test should reach at least 50%”. < / P > < p > FDA director Stephen Hahn In an article published in the Journal of the American Medical Association (JAMA) on August 7, Dr. Hahn said that the new crown vaccine must be strictly reviewed before it is approved for marketing. < / P > < p > the FDA also stressed that in vaccine clinical trials, a small number of groups, such as some ethnic minorities, the elderly and those at risk of complications, should be fully considered; and special groups, such as children and children, should be fully considered Pregnant women provide additional protection.